June 7, 2017 / 11:29 AM / 2 months ago

BRIEF-Kamada provides update on clinical program for alpha-1 antitrypsin IV treatment

June 7 (Reuters) - Kamada Ltd

* Provides update on clinical program for alpha-1 antitrypsin IV for treatment of graft-versus-host disease

* Kamada, Shire agreed INDA approved by U.S. FDA for phase 2/3 study evaluating alpha-1 antitrypsin for treatment of GVHD will be transferred to Kamada

* Kamada will take full ownership and responsibility for clinical development of g1-aat iv in this indication

* Kamada Ltd says Shire decided to transfer INDA to Kamada due to pipeline prioritization and slow recruitment rate in its current u.s. Study

* Kamada will assume control of, and onward funding for full G1-AAT iv program

* Kamada Ltd says intends to conduct an integrated clinical development program across both territories - u.s. And eu

* Kamada Ltd says as result of this decision, current part 1 of phase 2/3 study conducted in u.s. Is being halted by shire Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below